港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

579.360

+1.4270.25%

涨家数：14

跌家数：17

平家数：3

市盈率：- -

高：598.497

开：578.227

低：573.488

收：577.933

成交量：1.15亿

成交额：33.86亿

市值：3,682.12亿

流通市值：3,290.33亿

数据加载中...

总览新闻资讯

心玮医疗-B(06609)发布年度业绩股东应占溢利8333.5万元出血性卒中业务收入同比大幅增长223.2%

先瑞达医疗-B(06669)公布2025年业绩净利约1.19亿元同比增长128%

基石药业-B(02616)公布PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展及I/II期关键临床数据

《蓝筹》中生制药(01177.HK)全年纯利跌33% 基本溢利增31.4% 末期息5港仙

阿斯达克财经

华领医药-B(02552)委任欧阳丽妮为公司秘书

一品红(300723.SZ)子公司创新药APH03571片获得临床试验注册申请受理

荣昌生物(09995)出现大手卖出12.5万股，成交价$88.6，涉资1.108千万

阿斯达克财经

天圣制药曾因年报虚假引发索赔，部分案件已递交立案

“AI制药”的晶泰控股扭亏虚与实

华尔街见闻

老百姓大药房与信达生物深化战略合作携手共拓创新药市场

新股消息 | 据报闻泰医药拟赴港上市募资规模约为1亿至2亿美元

沛嘉医疗(09996)发布2025年度业绩：稳中求进、提质增效核心业务稳健增长

智通财经网

河北省定州市市场监管局开展医疗器械经营环节法规宣贯培训

中国质量新闻网

康宁杰瑞公布2025年度业绩及近期业务进展

汉方制药独家产品卷入行贿案上个月刚披露H股招股书

康方生物(09926)出现大手买入8.1万股，成交价$124.3，涉资1.007千万

阿斯达克财经

《大行》华泰证券：吉利德收购Ouro反映康诺亚(02162.HK)平台价值

阿斯达克财经

强业绩提振，港股通创新药逆市续涨，520880收复20日线！乐普生物-B绩后狂飙14%

港股异动 | 基石药业-B(02616)再涨超4% 核心商业化产品舒格利单抗获ESMO指南【I, A】级推荐

港股沛嘉医疗-B早盘涨超6%

每日经济新闻

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":579.3598,"timestamp":1774512495612,"preClose":577.93304,"halted":0,"volume":115336870,"delay":0,"changeRate":0.002469,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":1.426758,"latestTime":"03-26 16:00:00","open":578.2267,"high":598.49725,"low":573.4878,"amount":3386124743,"amplitude":0.043274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.004143,"increases":13,"decrements":20,"flats":0,"marketCap":368211528480,"floatMarketCap":329033220336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.043274,"preClose":577.93304,"low":573.4878,"pbRate":"5.179109","latestPrice":579.3598,"volume":115336870,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.004143,"peRate":-60.041027,"marketCap":368211528480,"floatMarketCap":329033220336,"timestamp":1774512495612,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":17,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622859250","title":"心玮医疗-B(06609)发布年度业绩 股东应占溢利8333.5万元 出血性卒中业务收入同比大幅增长223.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622859250","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622859250?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 18:50","pubTimestamp":1774522247,"startTime":"0","endTime":"0","summary":"智通财经APP讯，心玮医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收益4.08亿元，同比增长46.9%;毛利2.9亿元，同比增长59.3%;研发成本4076.1万元，同比减少30.8%;股东应占溢利8333.5万元，同比扭亏为盈;每股基本盈利2.21元。于2025财政年度，公司取得收益人民币4.083亿元，同比增长46.9%。集团取得股东应占净利润人民币8333.5万元，较上年度的股东应占净亏损约人民币1360万元实现重大扭亏为盈。基于前述原因，公司的出血性卒中业务收入在2025年同比增长223.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06609","BK1100","BK1574","BK1587"],"gpt_icon":0},{"id":"2622285850","title":"先瑞达医疗-B(06669)公布2025年业绩 净利约1.19亿元 同比增长128%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285850","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285850?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 17:09","pubTimestamp":1774516180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先瑞达医疗-B 公布2025年业绩，收益约6.45亿元，同比增长20.7%;毛利约4.76亿元，同比增长18.3%;年内溢利约1.19亿元，同比增长128%;每股基本盈利0.4元。2025年是产品获批的收获期，公司成熟的多元化研发技术组合的协同效应取得成果。于报告期间，公司共获得国家药监局及北京药监局对11款产品的注册批准，其中多项产品代表了公司的里程碑式发布。同时，公司继续扩大全球布局。公司的外周射频消融系统于2025年10月获得美国FDA的510认证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06669","BK1100","BK1574"],"gpt_icon":0},{"id":"2622858900","title":"基石药业-B(02616)公布PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展及I/II期关键临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622858900?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 17:09","pubTimestamp":1774516159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。在肺癌中展现强劲疗效：CS2009单药针对肺癌的I/II期初步疗效资料积极。截至2026年3月中旬，I期研究已共入组113例晚期实体瘤患者，中位元随访期约为6个月;II期研究已共入组85例患者。在TME中，PD-1和 CTLA-4的双重阻断作用通过与VEGFA的交联显著增强。同时，CS2009可优先结合PD-1和CTLA-4双阳性的肿瘤浸润T细胞，并最大程度上弱化对外周T细胞中CTLA-4调节通路的干扰。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK4023","LU1169589451.USD","BK1574","BK1161","PD","02616"],"gpt_icon":0},{"id":"2622483063","title":"《蓝筹》中生制药(01177.HK)全年纯利跌33% 基本溢利增31.4% 末期息5港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2622483063","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622483063?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:37","pubTimestamp":1774514220,"startTime":"0","endTime":"0","summary":"中国生物制药公布2025年度业绩，收入318.34亿人民币(下同)，按年升10.3%。股东应占溢利23.43亿元，按年跌33%；每股盈利13.02分。连同已派发中期股息每股5港仙，全年合共派发股息每股10港仙。过往派息公布日期派息事项派息内容2025/08/18中期业绩股息：港元 0.05002025/03/20末期业绩股息：港元 0.0400 2024/08/13中期业绩股息：港元 0.03002024/03/28末期业绩股息：港元 0.0300若撇除已终止经营业务、若干非现金项目及联营公司影响，基本溢利45.41亿元，按年升31.4%。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512865/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512865/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","HK0000165453.HKD","01477","BK1574","BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","BK1191","IE00BZ08YT58.USD","BK1521"],"gpt_icon":0},{"id":"2622583727","title":"华领医药-B(02552)委任欧阳丽妮为公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622583727","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622583727?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:34","pubTimestamp":1774514093,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华领医药-B(02552)发布公告，袁颕欣女士(袁女士)已辞任本公司公司秘书及不再担任根据香港联合交易所有限公司证券上市规则第 3.05条所规定的本公司授权代表，均自2026年3月26日起生效。在袁女士辞任后，董事会欣然宣布委任欧阳丽妮女士(欧阳女士)为本公司公司秘书及上市规则规定的第3.05条所规定授权代表，均自2026年3月26日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2622547837","title":"一品红(300723.SZ)子公司创新药APH03571片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2622547837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622547837?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:20","pubTimestamp":1774513225,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03571片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH03571是公司研制的拟用于携带 FLT3(全称：FMS-like tyrosine kinase3，译为 FMS 样酪氨酸激酶 3)突变的复发性或难治性急性髓系白血病(acutemyelogenous leukemia，简称：AML)成人患者的治疗药品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","159992","BK0239","BK1574","300723"],"gpt_icon":0},{"id":"2622837509","title":"荣昌生物(09995)出现大手卖出12.5万股，成交价$88.6，涉资1.108千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837509","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837509?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:08","pubTimestamp":1774512480,"startTime":"0","endTime":"0","summary":"[大手成交]荣昌生物(09995)在下午04:08出现大手卖出，成交量为12.5万，成交价为港币$88.6，涉资1.108千万。至目前为止，股价跌3.328%，今日最高价为$96.65，而最低价为$86.8，总成交量为633.599万股，总成交金额港币$5.81亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603267149/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603267149/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09995","BK0239","LU2488822045.USD","688331","LU1064130708.USD","LU1969619763.USD","BK1574","BK1583","LU2148510915.USD","LU2328871848.SGD","LU1064131003.USD"],"gpt_icon":0},{"id":"2622250834","title":"天圣制药曾因年报虚假引发索赔，部分案件已递交立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2622250834","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622250834?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 15:33","pubTimestamp":1774510380,"startTime":"0","endTime":"0","summary":"　　上海沪紫律师事务所刘鹏律师团队近日递交了一批次案件至法院立案，目前还在征集受损股民中。2025年11月8日，天圣制药公告收到中国证监会重庆证监局出具的《行政处罚决定书》。作为业内资深证券维权律师，刘鹏律师精准把握案件核心，诉讼经验丰富，索赔策略高效，为投资者争取最大权益，维权实力行业领先。专业决定胜算，经验确保结果，首选刘鹏律师，让您的索赔更稳妥、更高效！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-03-26/doc-inhsicuw2818235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2622783996","title":"“AI制药”的晶泰控股扭亏虚与实","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783996","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783996?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 14:52","pubTimestamp":1774507932,"startTime":"0","endTime":"0","summary":"港股“AI制药明星企业”晶泰控股交出了上市以来的首份扭亏答卷。\n2025年，晶泰控股实现营业收入8....","market":"sg","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3768447","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3768447","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“AI制药”的晶泰控股扭亏虚与实","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","AIPO","AGIX","02228","BK1574","BK1141","BK1617","CHAT","BK1191"],"gpt_icon":0},{"id":"2622783622","title":"老百姓大药房与信达生物深化战略合作 携手共拓创新药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783622","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783622?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 14:24","pubTimestamp":1774506240,"startTime":"0","endTime":"0","summary":"本报讯受处方外流持续推进影响，对于部分进院难度较大的创新药，零售药房已成为实现商业化落地、提升患者可及性的重要渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685418646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0502904849.HKD","BK1161","BK1589","603883","LU2097828474.EUR","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828557.USD","BK1583","HK0000165453.HKD","BK0209","159992","LU2242644610.SGD","01801","06978","BK1574","LU2097828714.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2622836858","title":"新股消息 | 据报闻泰医药拟赴港上市 募资规模约为1亿至2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622836858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622836858?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 14:23","pubTimestamp":1774506210,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体消息，成都闻泰医药科技股份有限公司Vincentage Pharma正考虑赴港上市，拟募资规模约为1亿至2亿美元。公司最受关注的管线是口服小分子GLP-1受体激动剂VCT220，也被称为CX11。公开信息显示，CX11已在中国进行II期临床试验，并显示出“有竞争力的减重效果”，其III期临床已于2024年底启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","09939","BK1574","159938"],"gpt_icon":0},{"id":"2622833544","title":"沛嘉医疗(09996)发布2025年度业绩：稳中求进、提质增效 核心业务稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833544","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833544?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 13:16","pubTimestamp":1774502207,"startTime":"0","endTime":"0","summary":"3月25日，沛嘉医疗(09996)发布了截至2025年12月31日止十二个月(“报告期”)的年度业绩。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260326/20260326131606_90636.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260326/20260326131606_90636.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09996","159891","BK1100","BK1574","BK1583"],"gpt_icon":0},{"id":"2622833510","title":"河北省定州市市场监管局开展医疗器械经营环节法规宣贯培训","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833510","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833510?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 13:15","pubTimestamp":1774502100,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 为进一步规范医疗器械经营秩序，压实企业主体责任，保障公众用械安全，近期，河北省定州市市场监督管理局对全市156家医疗器械经营企业开展了三期医疗器械经营环节法规宣贯培训。下一步，该局将以此次培训宣贯为契机，压紧压实企业质量安全主体责任，不断强化医疗器械质量监管，依法严厉打击违法违规行为，切实保障公众用械安全。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-26/doc-inhshxny2864385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","159883","09996","BK1574","BK1222","BK1583","09997"],"gpt_icon":0},{"id":"2622835709","title":"康宁杰瑞公布2025年度业绩及近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2622835709","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622835709?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 13:14","pubTimestamp":1774502040,"startTime":"0","endTime":"0","summary":"苏州2026年3月26日 /美通社/ -- 康宁杰瑞生物制药公布了截至2025年12月31日的2025年度业绩和近期业务进展。财务概览  2025年度实现营业收入566.24百万元人民币，其中归属于本公司的产品收入130.13百万元人民币。2025年度年内亏损113.95百万元人民币。财务状况安全稳健，截至2025年12月31日现金储备为1350.32百万元人民币。2025年4月，KN026联合白蛋白结合型多西他赛HB1801一线治疗HER2阳性复发转移性乳腺癌的Ⅲ期临床研究完成全部患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4919913_ZH19913_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","LU0348723411.USD","LU1992135399.USD","BK4148","BK1574","LU2322448957.HKD","LU1720051108.HKD","LU1992135472.HKD","LU1720051017.SGD","BK1161","09966","LU2272731600.USD","LU2473716301.USD","LU2357305700.SGD","BK4588","LU2272731782.SGD","LU2272731865.HKD","LU1548497426.USD","BK4512","LU2322448791.USD","IE00BFMHRM44.USD"],"gpt_icon":1},{"id":"2622887076","title":"汉方制药独家产品卷入行贿案 上个月刚披露H股招股书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887076","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887076?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:37","pubTimestamp":1774496231,"startTime":"0","endTime":"0","summary":"中国经济网北京3月26日讯 国家医保局网站3月24日通报了“张某猛药品销售行贿案”。2024年10月，河北省秦皇岛市山海关区人民法院依法组成合议庭，适用普通程序公开开庭审理了张某猛行贿、对非国家工作人员行贿案。　　汉方制药于2月25日向港交所递交了招股书，拟于主板上市。据招股书显示，汉方制药成立于2004年，从事中医药产品研发、生产及销售业务。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260326/32100470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2622880365","title":"康方生物(09926)出现大手买入8.1万股，成交价$124.3，涉资1.007千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2622880365","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622880365?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:34","pubTimestamp":1774496040,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午11:34出现大手买入，成交量为8.1万，成交价为港币$124.3，涉资1.007千万。至目前为止，股价升2.053%，今日最高价为$129.7，而最低价为$124.1，总成交量为880.26万股，总成交金额港币$11.197亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B5MMRT66.SGD","09926","LU0634319403.HKD","LU2476274720.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","BK1161","LU0348825331.USD","LU0348783233.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348735423.USD","LU1961090484.USD","LU0417516738.SGD","BK1574","LU0348766576.USD","LU0348784397.USD","LU0417516571.SGD","LU2476274308.USD","LU0348767384.USD","LU1720050803.USD","LU2778985437.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2622887191","title":"《大行》华泰证券：吉利德收购Ouro反映康诺亚(02162.HK)平台价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887191","media":"阿斯达克财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887191?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:21","pubTimestamp":1774495260,"startTime":"0","endTime":"0","summary":"华泰证券发表报告指，康诺亚-B公告吉利德将以16.75亿美元首付款、5亿美元里程碑并购Ouro，后者为承载CM336海外权益的NewCo。交易完成后，康诺亚依据Ouro股权将取得2.5亿元首付款及7,000万美元里程碑，同时继续享有CM336的销售分成权利。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0276","LU0531971595.HKD","BK1583","LU1934453819.USD","LU0164865239.USD","LU2148510915.USD","LU1064131003.USD","BK1574","BK1161","LU1328615791.USD","LU0871576103.HKD","LU1580142542.USD","BK0028","BK1587","LU1781817850.SGD","02162","601688","BK0188","LU1808992512.USD","BK0183","LU1979443071.USD","LU0039217434.USD","BK0012","LU1064130708.USD"],"gpt_icon":0},{"id":"2622882066","title":"强业绩提振，港股通创新药逆市续涨，520880收复20日线！乐普生物-B绩后狂飙14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882066","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882066?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:03","pubTimestamp":1774494180,"startTime":"0","endTime":"0","summary":"3月26日，港股通医药再度逆市表现，100%创新药研发标的——港股通创新药ETF华宝、港股医疗核心资产——港股通医疗ETF华宝双双高开，一度携手涨超1%！520880量价齐升，盘中收复20日线，实时成交超2亿元。　　创新药多股领跑，乐普生物-B盘中飙升逾14%站上半年线，领涨所有港股通标的。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-26/doc-inhshtfa2929921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","VXUS","520880","06978","BK1574","02157","BK4585","BK4588","159992"],"gpt_icon":0},{"id":"2622821058","title":"港股异动 | 基石药业-B(02616)再涨超4% 核心商业化产品舒格利单抗获ESMO指南【I, A】级推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821058","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821058?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 10:53","pubTimestamp":1774493593,"startTime":"0","endTime":"0","summary":"消息面上，3月25日，基石药业-B发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK1574","BK4585","02616","VXUS"],"gpt_icon":0},{"id":"2622444882","title":"港股沛嘉医疗-B早盘涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622444882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622444882?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 10:47","pubTimestamp":1774493260,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月26日，沛嘉医疗-B(09996.HK)早盘涨超6%，截至发稿涨6.69%，报6.06港元，成交额1185.39万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685222031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685222031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159891","09996","BK4585","BK1100","BK4588","BK1583","VXUS","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":294,"code":"91000000","status":"200"}]}}